Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (101-110 of 617) with videos related to

Pageof 62
Sort By:
Hepatology (Baltimore, Md.)|July 31, 2008
Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposureChia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, et al.
Hepatology (Baltimore, Md.)|March 31, 2009
A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard durationChung-Feng Huang, Chia-Yen Dai, Jee-Fu Huang, et al.
Hepatology (Baltimore, Md.)|May 1, 2010
Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin dosesChia-Yen Dai, Chung-Feng Huang, Jee-Fu Huang, et al.
Oncology|December 22, 2007
Long-term effects of interferon-based therapy for chronic hepatitis CMing-Lung Yu, Chung-Feng Huang, Chia-Yen Dai, et al.
Journal of Hepatology|May 29, 2021
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapyChung-Feng Huang, Yu-Ju Wei, Yu-Tse Wu, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 9, 2019
Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis BMing-Lun Yeh, Jee-Fu Huang, Chia-Yen Dai, et al.
Journal of Hepatology|January 15, 2024
Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric labelChih-Wen Wang, Po-Chin Huang, Chia-Yen Dai, et al.
Annals of Hepatology|March 8, 2025
Energy metabolism: An emerging therapeutic frontier in liver fibrosisIram Irshad, Saleh A Alqahtani, Kenichi Ikejima, et al.
Gut and Liver|December 31, 2025
Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular CarcinomaMing-Ying Lu, Jacky Chung-Hao Wu, Henry Horng-Shing Lu, et al.
Therapeutic Advances in Endocrinology and Metabolism|May 29, 2024
MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weightZiyan Pan, Maryam Al Khatry, Ming-Lung Yu, et al.
Pageof 62

Showing results (101-110 of 617) with videos related to

Sort By:
Pageof 62
Hepatology (Baltimore, Md.)|July 31, 2008
Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposureChia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, et al.
Hepatology (Baltimore, Md.)|March 31, 2009
A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard durationChung-Feng Huang, Chia-Yen Dai, Jee-Fu Huang, et al.
Hepatology (Baltimore, Md.)|May 1, 2010
Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin dosesChia-Yen Dai, Chung-Feng Huang, Jee-Fu Huang, et al.
Oncology|December 22, 2007
Long-term effects of interferon-based therapy for chronic hepatitis CMing-Lung Yu, Chung-Feng Huang, Chia-Yen Dai, et al.
Journal of Hepatology|May 29, 2021
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapyChung-Feng Huang, Yu-Ju Wei, Yu-Tse Wu, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 9, 2019
Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis BMing-Lun Yeh, Jee-Fu Huang, Chia-Yen Dai, et al.
Journal of Hepatology|January 15, 2024
Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric labelChih-Wen Wang, Po-Chin Huang, Chia-Yen Dai, et al.
Annals of Hepatology|March 8, 2025
Energy metabolism: An emerging therapeutic frontier in liver fibrosisIram Irshad, Saleh A Alqahtani, Kenichi Ikejima, et al.
Gut and Liver|December 31, 2025
Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular CarcinomaMing-Ying Lu, Jacky Chung-Hao Wu, Henry Horng-Shing Lu, et al.
Therapeutic Advances in Endocrinology and Metabolism|May 29, 2024
MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weightZiyan Pan, Maryam Al Khatry, Ming-Lung Yu, et al.
Pageof 62